Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 | |
Ankyra Therapeutics and Jenga Biosciences Announce Exclusive License Agreement for JEN-101 | |
Ankyra Therapeutics Announces First Patient Dosed in Phase 1 Trial Evaluating ANK-101 | |
Compass Therapeutics Announces Publication of Preclinical Data for CTX-8371 | |
Adimab Provides Year-End Update on 2023 Partnership Activities | |
Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors | |